9 Jun
2019

Top patent firms revealed; Deloitte makes major IP play; where Europe’s courts stand on FRAND; Microsoft IP chief on value creation; world's biggest biotech portfolios; and more

Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week

MONDAY 3rd June

Deloitte has closed a deal to acquire UK-based IP transactions and strategy advisory ClearView in a further sign that IP value creation is moving to the centre of the corporate agenda. Read more here

According to demand letters circulating in the Chinese media, memory maker Netac’s IP team is partnering with a patent pool formed by Panasonic, Toshiba and SanDisk. Read more here

Microsoft IP head Erich Andersen explains how the company’s IP vision has pivoted from a focus on direct monetisation to support of cloud computing and open source. Read more here

Consolidation in the chip industry continues with Infineon set to buy Cypress and bring together two players with plenty of experience in the patent secondary market. Read more here 

TUESDAY 4th June

Recent decisions in Germany, the UK, the Netherlands and France have shed much greater light on where the continent’s top patent litigation venues are heading on FRAND/SEP-related disputes. Read more here

India’s Patent Office has proposed simplifications to Form 27, which plays a role in compulsory licensing and injunctions, after complaints by Ericsson, Nokia, Huawei and others. Read more here

The IP3 patent deals platform has made key rule changes for 2019 to drum up more seller interest in what remains a buyers’ market. Read more here

WEDNESDAY 5th June

In advance of the online publication of the 2019 edition of the IAM Patent 1000, we reveal the key takeaways uncovered during the research process. Read more here

THURSDAY 6th June

The IAM Patent 1000 - the world's most comprehensive and authoritative guide to top patent law and attorney firms, as well as stand-out individuals - has now been published online. Read more here

Following successful invalidation petitions lodged by Vivo against Siemens, Oppo, Xiaomi and Meizu also face SEP assertions by the German company in China’s IP courts. Read more here

All the key takeaways from two days of Congressional hearings on legislative reform of the US patent eligibility regime which highlighted the progress made and big challenges ahead. Read more here

FRIDAY 7th June

Food and drug authorities will take responsibility for criminal IP investigations in China, as government re-shuffle continues. It’s good news for pharma IP owners – others may have questions. Read more here

Roche has the world’s largest biotech patent portfolio, according to a new IAM data report, with DowDuPont and Bayer rounding off the top three. Read more here

Recent assignments to Samsung and US software business Citrix Systems demonstrate that it’s more than just NPEs which are interested in Intellectual Ventures’ patent assets. Read more here

SATURDAY 8th June

In an opinion piece, the man whose invention was at the heart of the pivotal SCOTUS Alice decision argues that current patentable subject matter reform proposals in the US get a lot wrong. Read more here

Joff Wild

Author | Editor-in-chief

[email protected]

Joff Wild